CARsgen Therapeutics Holdings Limited (SEHK: 2171)
Health Care · Biotechnology · CN
HK$13.36
+1.14% today · -39.5% 1Y
CARsgen Therapeutics Holdings Limited (SEHK: 2171) operates in the Biotechnology industry within the Health Care sector. The company is valued at $958.31M and employs 355 people.
Over the last twelve months the share price has lost 39.5%, trading between 10.87 and 28.60.
Tweenvest scores CARsgen Therapeutics Holdings Limited across four factors: quality 30/100, value 83/100. Its strongest factor is value.
2171 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $958.31M
- Revenue (TTM)
- $20.11M
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 0.22
- 52-week high
- HK$28.60
- 52-week low
- HK$10.87
- Avg volume (3M)
- —
- Shares outstanding
- 562.26M
- Employees
- 355
- Next earnings
- —
About CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
- ISIN
- KYG1996C1006
- Founded
- 2014
- Listed since
- Jun 18, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.